Literature DB >> 23184143

Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model.

Ngoc H On1, Ryan Mitchell, Sanjot D Savant, Corbin J Bachmeier, Grant M Hatch, Donald W Miller.   

Abstract

The present study evaluates, both functionally and biochemically, brain tumor-induced alterations in brain capillary endothelial cells. Brain tumors were induced in Balb/c mice via intracranial injection of Lewis Lung carcinoma cells into the right hemisphere of the mouse brain using stereotaxic apparatus. Blood-brain barrier (BBB) permeability was assessed at various stages of tumor development, using both radiolabeled tracer permeability and magnetic resonance imaging with gadolinium diethylene-triamine-pentaacetate contrast enhancement (Gad-DTPA). The expression of the drug efflux transporter, P-glycoprotein (P-gp), in the BBB at various stages of tumor development was also evaluated by Western blot and immunohistochemistry. Median mouse survival following tumor cell injection was 17 days. The permeability of the BBB to (3)H-mannitol was similar in both brain hemispheres at 7 and 10 days post-injection. By day 15, there was a twofold increase in (3)H-mannitol permeability in the tumor bearing hemispheres compared to the non-tumor hemispheres. Examination of BBB permeability with Gad-DTPA contrast enhanced MRI indicated cerebral vascular permeability changes were confined to the tumor area. The permeability increase observed at the later stages of tumor development correlated with an increase in cerebral vascular volume suggesting angiogenesis within the tumor bearing hemisphere. Furthermore, the Gad-DPTA enhancement observed within the tumor area was significantly less than Gad-DPTA enhancement within the circumventricular organs not protected by the BBB. Expression of P-gp in both the tumor bearing and non-tumor bearing portions of the brain appeared similar at all time points examined. These studies suggest that although BBB integrity is altered within the tumor site at later stages of development, the BBB is still functional and limiting in terms of solute and drug permeability in and around the tumor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23184143      PMCID: PMC3555227          DOI: 10.1007/s11060-012-1006-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  43 in total

1.  Controversies in the management of patients with brain metastases.

Authors:  A W Chan; J S Loeffler
Journal:  Cancer J       Date:  2001 Mar-Apr       Impact factor: 3.360

2.  Epidemiology of brain metastases.

Authors:  Lakshmi Nayak; Eudocia Quant Lee; Patrick Y Wen
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

Review 3.  Small cell bronchogenic carcinoma: a distinct clinicopathologic entity.

Authors:  M H Cohen; M J Matthews
Journal:  Semin Oncol       Date:  1978-09       Impact factor: 4.929

4.  Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.

Authors:  Stephan Fellner; Björn Bauer; David S Miller; Martina Schaffrik; Martina Fankhänel; Thilo Spruss; Günther Bernhardt; Claudia Graeff; Lothar Färber; Harald Gschaidmeier; Armin Buschauer; Gert Fricker
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 5.  The seed and soil hypothesis: vascularisation and brain metastases.

Authors:  Isaiah J Fidler; Seiji Yano; Ruo-Dan Zhang; Takahashi Fujimaki; Corazon D Bucana
Journal:  Lancet Oncol       Date:  2002-01       Impact factor: 41.316

6.  Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis.

Authors:  H M Fathallah-Shaykh; L J Zhao; A I Kafrouni; G M Smith; J Forman
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

Review 7.  Multidrug resistance in brain tumors: roles of the blood-brain barrier.

Authors:  A Régina; M Demeule; A Laplante; J Jodoin; C Dagenais; F Berthelet; A Moghrabi; R Béliveau
Journal:  Cancer Metastasis Rev       Date:  2001       Impact factor: 9.264

Review 8.  Treatment options for brain metastases in patients with non-small-cell lung cancer.

Authors:  Sadaf Taimur; Martin J Edelman
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.075

Review 9.  The role of topotecan in the treatment of brain metastases.

Authors:  Eric T Wong; Anna Berkenblit
Journal:  Oncologist       Date:  2004

10.  Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors.

Authors:  Antonie Rice; Mary L Michaelis; Gunda Georg; Yanbin Liu; Brandon Turunen; Kenneth L Audus
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866

View more
  20 in total

Review 1.  Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Authors:  Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

2.  Contribution of protease-activated receptor 1 in status epilepticus-induced epileptogenesis.

Authors:  D Isaev; I Lushnikova; O Lunko; O Zapukhliak; O Maximyuk; A Romanov; G G Skibo; C Tian; G L Holmes; E Isaeva
Journal:  Neurobiol Dis       Date:  2015-04-02       Impact factor: 5.996

Review 3.  SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers.

Authors:  Marilyn E Morris; Vivian Rodriguez-Cruz; Melanie A Felmlee
Journal:  AAPS J       Date:  2017-06-29       Impact factor: 4.009

Review 4.  Best Practices for Preclinical In Vivo Testing of Cancer Nanomedicines.

Authors:  Danielle M Valcourt; Chintan H Kapadia; Mackenzie A Scully; Megan N Dang; Emily S Day
Journal:  Adv Healthc Mater       Date:  2020-05-04       Impact factor: 9.933

Review 5.  Embracing rejection: Immunologic trends in brain metastasis.

Authors:  S Harrison Farber; Vadim Tsvankin; Jessica L Narloch; Grace J Kim; April K S Salama; Gordana Vlahovic; Kimberly L Blackwell; John P Kirkpatrick; Peter E Fecci
Journal:  Oncoimmunology       Date:  2016-04-11       Impact factor: 8.110

6.  Salicylic acid analogues as chemical exchange saturation transfer MRI contrast agents for the assessment of brain perfusion territory and blood-brain barrier opening after intra-arterial infusion.

Authors:  Xiaolei Song; Piotr Walczak; Xiaowei He; Xing Yang; Monica Pearl; Jeff W M Bulte; Martin G Pomper; Michael T McMahon; Mirosław Janowski
Journal:  J Cereb Blood Flow Metab       Date:  2016-03-15       Impact factor: 6.200

7.  Comparison of Linear and Cyclic His-Ala-Val Peptides in Modulating the Blood-Brain Barrier Permeability: Impact on Delivery of Molecules to the Brain.

Authors:  Ahmed Alaofi; Ngoc On; Paul Kiptoo; Todd D Williams; Donald W Miller; Teruna J Siahaan
Journal:  J Pharm Sci       Date:  2016-02       Impact factor: 3.534

8.  Rapid and reversible enhancement of blood-brain barrier permeability using lysophosphatidic acid.

Authors:  Ngoc H On; Sanjot Savant; Myron Toews; Donald W Miller
Journal:  J Cereb Blood Flow Metab       Date:  2013-09-18       Impact factor: 6.200

9.  Isolated brain metastasis as a late recurrence of completely resected non-small cell lung cancer.

Authors:  Lixia Ju; Mingquan Han
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

Review 10.  Which drug or drug delivery system can change clinical practice for brain tumor therapy?

Authors:  Tali Siegal
Journal:  Neuro Oncol       Date:  2013-03-15       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.